Cannabis Science Inc (fka CBIS)

[Eternalist]

New Colombia Resources Inc. Appoints Dr. Robert Melamede PhD as Scientific Advisor for Research and Approval of Cannabis Based Pharmaceutical Products in Colombia

New Colombia Resources Inc. Appoints Dr. Robert Melamede PhD as Scientific Advisor for Research and Approval of Cannabis Based Pharmaceutical Products in Colombia

SUNNY ISLES BEACH, FL--(Marketwired - Apr 22, 2014) - New Colombia Resources, Inc. (OTCQB: NEWC) ("New Colombia" or "the Company"), a U.S. company with coal and other resource assets in Colombia, is pleased to announce the appointment of Dr. Robert J. Melamede PhD, President of Cannabis Science, Inc., as a scientific advisor to gain approval to legally research and market cannabis based pharmaceutical products in Colombia and other Latin American countries. The Company is discussing a collaborative effort with Cannabis Science, Inc.

Dr. Melamede, retired Chairman of the Biology department of the University of Colorado at Colorado Springs, is a world renowned leader in Cannabis research with many years investigating the human body's endocannabinoid system and its reaction to cannabinoids. Dr. Melamede has made many presentations around the globe explaining the benefits of cannabinoids for cancer patients.

"I am thrilled to finally start this project in Colombia given its history and rising economic standing on the world stage. Many patients in Latin America will benefit from the research done in Colombia," stated Dr. Robert Melamede PhD.

New Colombia Resources will form a joint venture to include U.S. and Colombian investors, universities, and pharmaceutical partners. New Colombia will work closely with government agencies to allow them permission to conduct research of cannabis based formulations. They will hire a reputable law firm to handle government approvals, lobbying, and public relations. The joint venture will conduct studies in different regions of Colombia with high incidences of the specific illness for which treatment is being researched without regard to socio-economic status. New Colombia Resources will lead the effort to gain approval from INVIMA (National Institute of Food & Drug Vigilance) to market these products in Colombia and other Latin American countries.

"Dr. Melamede and I have been discussing research in Colombia for a few years and we feel now is the right time, I'm very happy to work with him again. As a Colombian American I truly believe this is a project of national interest for Colombia. We will make every effort to follow strict international standards in our studies working with universities, research institutions, and pharmaceutical partners throughout Colombia," stated John Campo President of New Colombia Resources, Inc.

The venture will focus its initial efforts on a skin cancer cream and treatments for epilepsy including Dravet syndrome in children. The company will produce a high cannabinoid (CBD) strain low in tetra hydrochloride (THC) similar to the "Charlotte's Web" strain being used in Colorado. Families of children with Dravet Syndrome have been moving to Colorado to legally gain access to these strains and administer it to their children with miraculous results. New Colombia Resources will work with pharmaceutical companies to manufacture products with controlled doses like all INVIMA approved medicines.

Colombia has surpassed Argentina as the third largest economy in Latin America behind Brazil and Mexico. The government of Colombia is injecting US$ 25 Billion into the economy through infrastructure investments in an effort to unleash an economic growth spurt. New Colombia Resources will be a direct beneficiary of these investments by supplying raw building materials for these projects and using the new infrastructure to transport their high quality metallurgical coal to export markets. The Company will provide an update of their rock and coal mining operations in the coming days.

http://online.wsj.com/article/PR-CO-20140422-906695.html